New York approves Quest Diagnostics' Haystack MRD test for solid tumor cancer monitoring

Quest Diagnostics' Haystack MRD test, a liquid biopsy detecting residual or recurring solid tumor cancers, received approval from New York State's health department. This approval allows the test to be used in all 50 U.S. states, expanding access for patients and clinicians. The test offers earlier detection of cancer recurrence and treatment response, supported by clinical studies including one at Memorial Sloan Kettering Cancer Center. This milestone highlights the test's accuracy and potential to improve cancer patient care nationwide.